A Personalized Medicine Approach to Ovulation Induction/ovarian Stimulation: Development of a Predictive Model and Online Calculator from Level-I Evidence

Overview

Journal Fertil Steril

Specialty Reproductive Medicine

Date 2022 Feb 7

PMID 35125179

Authors

Irene Souter

Fangbai Sun

Heping Zhang

Michael P Diamond

Richard S Legro

Robert A Wild

Karl R Hansen

Nanette Santoro

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate the probability of clinical or multiple pregnancy during ovulation induction (OI)/ovarian stimulation (OS).

Design: Secondary analysis of two multicenter randomized clinical trials (combined).

Setting: Multicenter.

Patients: A total of 750 women with polycystic ovary syndrome and 900 women with unexplained infertility.

Interventions: Ovulation induction/OS with either timed intercourse (polycystic ovary syndrome) or intrauterine insemination.

Main Outcome Measures: Clinical and multiple pregnancy rates/cycle, cumulative pregnancy rates. Age, body mass index, parity, diagnosis, medication, markers of ovarian reserve, and ovarian response were considered in multivariable regression models for clinical, multiple, and cumulative pregnancy rates. Receiver operating characteristic curves were created for clinical and multiple pregnancy rates.

Results: Younger patient and partner age, treatment type, lower body mass index, and medication dose were all associated with clinical pregnancy. Variables associated with multiple pregnancy included the abovementioned variables (except age), in addition to diagnosis, parity, higher antral follicle count, antimüllerian hormone levels, and ovarian response. Gonadotropin use was associated with multiple pregnancy, with progressively increasing odds ratios (cycles 1-4). Receiver operating characteristic curves indicated the model's predictive power to be fair for clinical pregnancy (areas under the curve [95% confidence interval {CI}]: 0.78 [0.75-0.81] for cycle 1 and 0.70 [0.64-0.75] for cycle 4) and good-to-excellent for multiple pregnancy (areas under the curve [95% CI]: 0.78 [0.72-0.84] for cycle 1 and 0.86 [0.78-0.93] for cycle 4). Partner age, lower medication dose, parity, antimüllerian hormone levels, and diagnosis were associated with cumulative pregnancy rates.

Conclusions: Using the majority of the factors known to predict the outcome of OI/OS cycles, we constructed an easy-to-use formula that may predict individualized chances of clinical and multiple pregnancy for commonly used fertility treatments (https://pregnancyprediction.medicine.yale.edu/CalDirect.html).

Clinical Trial Registration Numbers: Assessing Multiple Intrauterine Gestations after Ovulation Stimulation NCT01044862; PPCOSII NCT00719186.

Citing Articles

Race and ethnicity expression in reproductive endocrinology and infertility research studies compared with other obstetrics and gynecology subspecialty studies.

Roshong A, Rosalik K, Carson S, Spilman L, Luizzi J, Plowden T F S Rep. 2024; 5(3):304-311.

PMID: 39381662 PMC: 11456638. DOI: 10.1016/j.xfre.2024.06.001.

Prognosis-based management of unexplained infertility-why not?.

Shingshetty L, Wang R, Feng Q, Maheshwari A, Mol B Hum Reprod Open. 2024; 2024(2):hoae015.

PMID: 38716407 PMC: 11075788. DOI: 10.1093/hropen/hoae015.

Predicting success of intrauterine insemination using a clinically based scoring system.

Zippl A, Wachter A, Rockenschaub P, Toth B, Seeber B Arch Gynecol Obstet. 2022; 306(5):1777-1786.

PMID: 36069921 PMC: 9519724. DOI: 10.1007/s00404-022-06758-z.

References

Diamond M, Legro R, Coutifaris C, Alvero R, Robinson R, Casson P . Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med. 2015; 373(13):1230-40. PMC: 4739644. DOI: 10.1056/NEJMoa1414827. View

Hansen K, He A, Styer A, Wild R, Butts S, Engmann L . Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation-intrauterine insemination. Fertil Steril. 2016; 105(6):1575-1583.e2. PMC: 4893990. DOI: 10.1016/j.fertnstert.2016.02.020. View

Huang H, Hansen K, Factor-Litvak P, Carson S, Guzick D, Santoro N . Predictors of pregnancy and live birth after insemination in couples with unexplained or male-factor infertility. Fertil Steril. 2012; 97(4):959-67. PMC: 3319287. DOI: 10.1016/j.fertnstert.2012.01.090. View

Diamond M, Mitwally M, Casper R, Ager J, Legro R, Brzyski R . Estimating rates of multiple gestation pregnancies: sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial. Contemp Clin Trials. 2011; 32(6):902-8. PMC: 3708642. DOI: 10.1016/j.cct.2011.07.009. View

Steiner A, Pritchard D, Stanczyk F, Kesner J, Meadows J, Herring A . Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA. 2017; 318(14):1367-1376. PMC: 5744252. DOI: 10.1001/jama.2017.14588. View

Mumford S, Legro R, Diamond M, Coutifaris C, Steiner A, Schlaff W . Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2016; 101(9):3288-96. PMC: 5010565. DOI: 10.1210/jc.2016-1340. View

Guzick D, SULLIVAN M, Adamson G, Cedars M, Falk R, Peterson E . Efficacy of treatment for unexplained infertility. Fertil Steril. 1998; 70(2):207-13. DOI: 10.1016/s0015-0282(98)00177-0. View

Souter I, Dimitriadis I, Baltagi L, Meeker J, Petrozza J . Elevated day 3 follicle-stimulating hormone in younger women: is gonadotropin stimulation/intrauterine insemination a good option?. Am J Obstet Gynecol. 2014; 211(1):62.e1-8. DOI: 10.1016/j.ajog.2014.01.031. View

Simon C, Sakkas D, Gardner D, Critchley H . Precision medicine in human reproduction. Special Issue. Biol Reprod. 2019; 101(6):1075. DOI: 10.1093/biolre/ioz193. View

10.

. Evidence-based treatments for couples with unexplained infertility: a guideline. Fertil Steril. 2020; 113(2):305-322. DOI: 10.1016/j.fertnstert.2019.10.014. View

11.

Goldman R, Batsis M, Petrozza J, Souter I . Patient-specific predictions of outcome after gonadotropin ovulation induction/intrauterine insemination. Fertil Steril. 2014; 101(6):1649-55.e1-2. DOI: 10.1016/j.fertnstert.2014.02.028. View

12.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

13.

Legro R, Brzyski R, Diamond M, Coutifaris C, Schlaff W, Casson P . Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014; 371(2):119-29. PMC: 4175743. DOI: 10.1056/NEJMoa1313517. View

14.

Berker B, Kahraman K, Taskin S, Sukur Y, Sonmezer M, Atabekoglu C . Recombinant FSH versus clomiphene citrate for ovarian stimulation in couples with unexplained infertility and male subfertility undergoing intrauterine insemination: a randomized trial. Arch Gynecol Obstet. 2011; 284(6):1561-6. DOI: 10.1007/s00404-011-1997-4. View

15.

Legro R, Kunselman A, Brzyski R, Casson P, Diamond M, Schlaff W . The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemp Clin Trials. 2012; 33(3):470-81. PMC: 3312939. DOI: 10.1016/j.cct.2011.12.005. View